title: Developing anti-neoplastic biotherapeutics against eIF4F.
abstract: Biotherapeutics have revolutionized modern medicine by providing medicines that would not have been possible with small molecules. With respect to cancer therapies, this represents the current sector of the pharmaceutical industry having the largest therapeutic impact, as exemplified by the development of recombinant antibodies and cell-based therapies. In cancer, one of the most common regulatory alterations is the perturbation of translational control. Among these, changes in eukaryotic initiation factor 4F (eIF4F) are associated with tumor initiation, progression, and drug resistance in a number of settings. This, coupled with the fact that systemic suppression of eIF4F appears well tolerated, indicates that therapeutic agents targeting eIF4F hold much therapeutic potential. Here, we discuss opportunities offered by biologicals for this purpose.
authors.affiliation: Department of Biochemistry, McGill University, McIntyre Medical Sciences Building, Rm 810, 3655 Drummond St., Montreal, QC, H3G 1Y6, Canada.
authors.forename: Jutta
authors.initials: J
authors.lastname: Steinberger
authors.affiliation: Department of Biochemistry, McGill University, McIntyre Medical Sciences Building, Rm 810, 3655 Drummond St., Montreal, QC, H3G 1Y6, Canada.
authors.forename: Jennifer
authors.initials: J
authors.lastname: Chu
authors.affiliation: Department of Biochemistry, McGill University, McIntyre Medical Sciences Building, Rm 810, 3655 Drummond St., Montreal, QC, H3G 1Y6, Canada.
authors.forename: Rayelle Itoua
authors.initials: RI
authors.lastname: Maïga
authors.affiliation: Department of Biochemistry, McGill University, McIntyre Medical Sciences Building, Rm 810, 3655 Drummond St., Montreal, QC, H3G 1Y6, Canada.
authors.forename: Katia
authors.initials: K
authors.lastname: Sleiman
authors.affiliation: Department of Biochemistry, McGill University, McIntyre Medical Sciences Building, Rm 810, 3655 Drummond St., Montreal, QC, H3G 1Y6, Canada. jerry.pelletier@mcgill.ca.|The Rosalind and Morris Goodman Cancer Research Center, McGill University, Montreal, QC, H3G 1Y6, Canada. jerry.pelletier@mcgill.ca.|Department of Oncology, McGill University, Montreal, QC, H3G 1Y6, Canada. jerry.pelletier@mcgill.ca.
authors.forename: Jerry
authors.initials: J
authors.lastname: Pelletier
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002471:Cell Transformation, Neoplastic / Q000378:metabolism / Q000473:pathology; D055808:Drug Discovery; D039562:Eukaryotic Initiation Factor-4F / Q000037:antagonists & inhibitors* / Q000378:metabolism; D006801:Humans; D050504:Oncolytic Viruses / Q000187:drug effects / Q000378:metabolism; D014176:Protein Biosynthesis / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; D039562:Eukaryotic Initiation Factor-4F
keywords: 4EBP; Antisense; Biotherapeutics; Cancer therapeutics; PDCD4; Translational control; eIF4A; eIF4F